Amgen Corp - AMGN Net Assets per Single Share

Amgen Inc. (AMGN) is minimizing patent risks through the development of biosimilars and expansion into cardiology. The book value per share of the company, as reported by the GURU.Markets platform, confirms this growth, and the value of 21.72 shows the current magnitude of the metric. The asset is considered a defensive asset due to stable demand for drugs. The biotechnological ecosystem relies on M&A deals despite pricing pressure from the US Inflation Reduction Act.

This metric is calculated as the ratio of equity to the number of shares outstanding, reflecting the actual value of the business's net assets minus all liabilities. For Amgen Inc. (AMGN), the trend of this metric confirms the effectiveness of the Horizon Therapeutics acquisition and investments in oncology. An increase in this value indicates the capitalization of innovations, including the drug MariTide. The published book value per share allows for the timely identification of dilution risks or asset impairment.